Codiak BioSciences (CDAK)
NASDAQ:CDAK

Codiak BioSciences Stock Price & Analysis

248 Followers

CDAK Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$0.59 - $15.08
Previous Close$0.74
Volume23.20K
Average Volume (3M)308.35K
Market CapN/A
Enterprise ValueN/A
Total Cash (Recent Filing)$51.76M
Total Debt (Recent Filing)$61.28M
Price to Earnings (P/E)-1.1
Beta4.11
Next EarningsMar 15, 2023
Next Dividend Ex-DateN/A
Dividend YieldN/A
EPS (TTM)-0.68
Shares Outstanding36,829,626
R-Squared0.22
Standard Deviation0.41
10 Day Avg. Volume100,735
30 Day Avg. Volume308,350
Price to Book (P/B)0.65
Price to Sales (P/S)0.81
Price to Cash Flow (P/CF)N/A
P/FCF Ratio-0.40
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Price Target Upside89.19% Upside
Rating ConsensusHold
Alpha-0.06
Number of Analyst Covering1


Financials


Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.

---

CDAK FAQ

What was Codiak BioSciences’s price range in the past 12 months?
Codiak BioSciences lowest stock price was $0.59 and its highest was $15.08 in the past 12 months.
    What is Codiak BioSciences’s market cap?
    Currently, no data Available
    When is Codiak BioSciences’s upcoming earnings report date?
    Codiak BioSciences’s upcoming earnings report date is Mar 15, 2023 which is in 109 days.
      How were Codiak BioSciences’s earnings last quarter?
      Codiak BioSciences released its earnings results on Nov 03, 2022. The company reported -$0.77 earnings per share for the quarter, missing the consensus estimate of -$0.718 by -$0.052.
        Is Codiak BioSciences overvalued?
        According to Wall Street analysts Codiak BioSciences’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Codiak BioSciences pay dividends?
          Codiak BioSciences does not currently pay dividends.
          What is Codiak BioSciences’s EPS estimate?
          Codiak BioSciences’s EPS estimate is -$0.39.
            How many shares outstanding does Codiak BioSciences have?
            Codiak BioSciences has 36,829,624 shares outstanding.
              What happened to Codiak BioSciences’s price movement after its last earnings report?
              Codiak BioSciences reported an EPS of -$0.77 in its last earnings report, missing expectations of -$0.718. Following the earnings report the stock price went down -13.253%.
                Which hedge fund is a major shareholder of Codiak BioSciences?
                Among the largest hedge funds holding Codiak BioSciences’s share is Flagship Pioneering Inc.. It holds Codiak BioSciences’s shares valued at 3M.

                  ---

                  Codiak BioSciences Stock Smart Score

                  N/A
                  Not Ranked
                  1
                  2
                  3
                  4
                  5
                  6
                  7
                  8
                  9
                  10

                  Technicals

                  SMA
                  Negative
                  20 days / 200 days
                  Momentum
                  -94.83%
                  12-Months-Change

                  Fundamentals

                  Return on Equity
                  -47.77%
                  Trailing 12-Months
                  Asset Growth
                  -15.33%
                  Trailing 12-Months
                  This stock does not have enough of the key information we need to rate it accurately. Smart Score is calculated for stocks traded in Nasdaq, NYSE, TSE and LSE with a market cap above $30M and average 3 months trading volume above $30K.
                  Learn more about TipRanks Smart Score

                  Company Description

                  Codiak BioSciences

                  Codiak BioSciences Inc is a development-stage biopharmaceutical company focused on the development of exosome-based therapeutics aimed at treating a broad range of diseases, including oncology, neuro-oncology, neurology, neuromuscular disease, infectious disease and rare disease.

                  ---

                  Forecast EPS vs Actual EPS


                  Similar Stocks
                  Company
                  Price & Change
                  Follow
                  AbbVie
                  Amgen
                  Gilead Sciences
                  Moderna
                  Vertex Pharmaceuticals

                  Popular Stocks

                  ---
                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis